0
Eli Lilly announced that it has issued royalty-free, non-exclusive voluntary licenses to Indian pharmaceutical manufacturers of generic medicines, Cipla Ltd., Lupin Ltd. and Sun Pharmaceutical Industries Ltd., who are collaborating with Lilly to accelerate and expand the availability of baricitinib in India.
Lilly is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses.
These voluntary licensing agreements will ensure high quality manufacturing and accessibility of baricitinib during this pandemic improving the local treatment options available to positively impact the lives of people who are currently battling Eli Lilly signs agreements with Cipla, Lupin and Sun Pharma -19 in India.
Lilly inks agreement with Cipla, Lupin, Sun Pharma for commercialisation of COVID-19 drug baricitinib
Lilly inks agreement with Cipla, Lupin, Sun Pharma for commercialisation of COVID-19 drug baricitinib
10 May 2021 | News These voluntary licensing agreements will ensure high quality manufacturing and accessibility of baricitinib during this pandemic improving the local treatment options available to positively impact the lives of people who are currently battling COVID-19 in India
Source credit: Shutterstock
Eli Lilly and Company has announced that it has issued royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Cipla Ltd, Lupin Ltd and Sun Pharmaceutical Industries Ltd, who are collaborating with Lilly to accelerate and expand the availability of baricitinib in India. Lilly is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses.
3 Indian Firms To Make, Sell US s Eli Lilly s Baricitinib Drug For Covid Treatment The three Indian drugmakers - Cipla Ltd, Lupin Ltd and Sun Pharma - will collaborate with U.S.-based Lilly to help make and sell baricitinib in India.
Updated: May 10, 2021 1:16 pm IST
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
The agreements will bolster India s arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab.
US pharma giant Eli Lilly has issued royalty-free, non-exclusive voluntary licences to three Indian drug makers – Cipla, Sun Pharmaceuticals and Lupin – to manufacture and distribute Baricitinib, which is being used to treat Covid-19.
Earlier, Gilead too had signed non-exclusive voluntary licensing agreements with Indian pharmaceutical companies to expand the production of Remdesivir, a widely used anti-Covid drug.
“The voluntary licensing agreements will ensure high-quality manufacturing and accessibility of Baricitinib during this pandemic, improving the local treatment options available to positively impact the lives of people who are currently battling Covid-19 in India,” Eli Lilly said in a statement. The firm added that discussions were also taking place with other Indian players for the grant of voluntary licences to manufacture Baricitinib, which has recently found favour among clinicians for the treatment of Covid-19.
Lilly signs agreements with Cipla, Lupin and Sun Pharma for Baricitinib
May 10, 2021
US pharma also in discussions with other Indian manufacturers to grant additional licences
The US-based pharmaceutical company Eli Lilly and Company (Lilly) has issued royalty-free, non-exclusive voluntary licences to Indian pharmaceutical manufacturers of generic medicines – Cipla Ltd, Lupin Ltd and Sun Pharmaceutical Industries Ltd – who are collaborating with it to accelerate and expand the availability of Baricitinib for the treatment of Covid 19 in India, the company said in a release on Monday.
It is to be noted that Lilly received permission on May 3 for restricted emergency use by the Central Drugs Standard Control Organisation (CDSCO) for Baricitinib to be used in combination with Remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECM